“That being said, we continue to have a priority to do business development. So you should not necessarily expect a slowdown.”

In context

“are confident in the continued growth that we will drive for KEYTRUDA. Robert Davis: Yeah. And Chris, on the business development question. As Caroline noted in the prepared remarks, we continue to have ample firepower to do deals. And while I can tell you, I feel very confident and I know the team feels very confident about the progress we're making with our internal pipeline and with the BD we've already done. If you look forward, we're going to be -- we've either recently announced or will be announcing a number of important Phase III assets across oncology with basically every area of the business, cardiometabolic, what we see in vaccines as well as important upcoming launches. We've talked about V116 data, sotatercept. We can go down the line. So I feel very good about the progress. That being said, we continue to have a priority to do business development. So you should not necessarily expect a slowdown. If and when assets that bring important scientific opportunities present themselves, where we see an alignment with strategy and where we can see value creation, we have the capacity and we will be and are willing to act on those. So we’re actively looking and we’ll continue to drive deals because while I feel very good about where we are, we’re talking about trying to build a sustainable engine well into the next decade. And we want to continue to add to the firepower we have coming out of our own discovery and development labs as well. Peter Dannenbaum: Great. Thanks, Chris. Next question please, Cedric. Operator: Yes. Our next question comes from Dana Graybosch with Leerink Partners. Your line is open. Daina Graybosch: Hello. I have a question – thank you for the question -- on KEYTRUD”